Structure Therapeutics Says Aleniglipron Achieved Up To 16.2% Weight Loss At 72 Weeks In ACCESS Open-Label Extension With No Plateau; Says Phase 1/2a ACCG-2671 SAD Trial Showed 3.3% Weight Loss

뉴스 본문을 불러오고 있어요.

Structure Therapeutics Says Aleniglipron Achieved Up To 16.2% Weight Loss At 72 Weeks In ACCESS Open-Label Extension With No Plateau; Says Phase 1/2a ACCG-2671 SAD Trial Showed 3.3% Weight Loss | 웨이프 WAPE

Structure Therapeutics Says Aleniglipron Achieved Up To 16.2% Weight Loss At 72 Weeks In ACCESS Open-Label Extension With No Plateau; Says Phase 1/2a ACCG-2671 SAD Trial Showed 3.3% Weight Loss

기사 요약

관련 종목

댓글 —